Concure’s New $2.5M Funding to Boost Patient Access to its Radioactive Seed Treatment

Concure’s New $2.5M Funding to Boost Patient Access to its Radioactive Seed Treatment
Concure Oncology plans to use $2.5 million in new funding to help make its targeted radiation treatment option increasingly available to early-stage breast cancer patients. Specifically, the funding round is expected to allow Concure to double its field sales organization and to focus on training new clinicians nationwide on its Breast Microseed Treatment. Within the last year, the company added to its team several leading breast cancer treatment experts who plan to improve the next-generation device and treatment. “This new financing marks an exciting inflection point for the team at Concure Oncology as well as the patients that we treat, now and moving forward,” said Kevin Kelley, Concure chief financial officer, in a press release. “Combined with the team of experts that we’ve brought on in the last year and recent major shifts in treatment and therapy, women dealing with breast cancer now should have a much more optimistic path forward.” A form of accelerated partial breast irradiation, the minimally invasive treatment has been proven safe, effective, and convenient with few side effects. The technique is also known as low-dose-rate brachytherapy, a procedure that involves placing radioactive
Subscribe or to access all post and page content.